IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
IRADIMED reported record Q3 2026 revenue of $24.2 million, up 14% year-over-year, with GAAP diluted EPS of $0.51 (+17% YoY) and non-GAAP EPS of $0.55. Bookings set records on the 3870 MR IV pump launch, with domestic pump channel bookings up 45% YoY and over 70% of pump bookings in the higher-capacity 'quad stack' configuration; gross margin improved sequentially to 76%. Management guided Q4 revenue to $25.0-$26.5 million, reaching a $100 million annual run rate, but narrowed full-year guidance ranges, trimming the top end of revenue and EPS.
Key figures
- Eps
- 0.51
- Revenue
- 24203000
- Guidance
- Q4 2026 revenue $25.0M-$26.5M, GAAP diluted EPS $0.53-$0.57, non-GAAP diluted EPS $0.57-$0.61; FY2026 revenue $91.6M-$93.1M (from $91.0M-$96.0M), GAAP EPS $1.90-$1.94 (from $1.90-$2.05), non-GAAP EPS $2.07-$2.11 (from $2.06-$2.21)
- Revenue Yoy
- 14%
- Non gaap eps
- 0.55
- Nine month fcf
- 20103000
- Gaap net income
- 6506000
- Gross margin q3
- 76%
- Free cash flow q3
- 6784000
- Dividend per share
- 0.2
- Nine month revenue
- 66648000
- Non gaap net income
- 7122000
- Cash and equivalents
- 63288000
- Operating cash flow q3
- 6996000
- Q4 revenue run rate target
- $100.0 million
- Domestic pump channel bookings yoy
- 45%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.